Birchview Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Birchview Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,000	Closed	-$117K	–	57
2022 Q4	$117K	Hold	20,000	–	–	0.08%	52
2022 Q3	$134K	Hold	20,000	–	–	0.09%	53
2022 Q2	$84K	Hold	20,000	–	–	0.06%	55
2022 Q1	$67K	Hold	20,000	–	–	0.05%	62
2021 Q4	$63K	Hold	20,000	–	–	0.04%	66
2021 Q3	$65K	Hold	20,000	–	–	0.04%	64
2021 Q2	$84K	Hold	20,000	–	–	0.05%	62
2021 Q1	$100K	Buy	+20,000	New	+$162K	0.06%	54

Birchview Capital's CNCE Position: Q1 2023 in Review

Birchview Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 20,000 shares — an estimated $117K sold.

Birchview Capital first reported a position in CNCE in Q1 2021 and held it in 8 quarters. The position peaked at $134K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Birchview Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Birchview Capital sold 20,000 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $117K.
Birchview Capital first reported a position in Concert Pharmaceuticals, Inc. in Q1 2021 and held it in 8 quarters.
Birchview Capital's Concert Pharmaceuticals, Inc. position peaked at $134K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Birchview Capital's 13F filing for Q1 2023, filed 12 May 2023.